Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry

#450

Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.

Aim(s): We initiated a multi-institutional, prospective and board reviewed registry for patients treated with Peptide receptor radionuclide therapy in Germany in 2009.

Materials and methods: In five centers, 297 patients were registered. Primary tumors were mainly derived from the pancreas (117/297), small intestine (80/297) whereas 56 were of unknown primary. Most tumors were well-differentiated with a median Ki-67 proliferation rate of 5% (range 0.9 to 70). Peptide receptor radionuclide therapy was performed using mainly Yttrium-90 and/or Lutetium-177 as radionuclides in 1-8 cycles.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hörsch D, Ezziddin S, Haug A, Gratz K, Dunkelmann S,

Keywords: PRRT, Yttrium, Lutetium, SMS Receptor,

To read the full abstract, please log into your ENETS Member account.